Miller School Selected for National NF2 Tumor Clinical Trial

Author: Richard Westlund
Published On: 07/01/22

Dr. Dinh is the principal investigator for the University of Miami site in the Innovative Trial for Understanding the Impact of Targeted Therapies in Neurofibromatosis Type 2 (INTUITT-NF2). The sponsor site, Massachusetts General Hospital, is led by Scott Plotkin, M.D., Ph.D., renowned NF2 researcher, neuro-oncologist, and Giovanni Armenise – Harvard Professor of Neurology.

Other sites include Johns Hopkins Hospital, New York University Langone Medical Center, University of California Los Angeles Medical Center, and the Mayo Clinic Hospital in Rochester, Minnesota. The initiative has been supported by the Children’s Tumor Foundation’s visionary Synodos Consortium for NF2 research collaborative.

“Joining this very exclusive INTUITT-NF2 clinical trial gives national recognition to our NF2 team, our multidisciplinary skull base tumor program at UHealth,” said Fred F. Telischi, M.E.E., M.D., chairman of otolaryngology, professor of neurological surgery and biomedical engineering, and the James R. Chandler Chair in Otolaryngology. “This trial is so incredibly important because it is the last step of a comprehensive translational research pipeline bringing novel and new therapies from the bench to the bedside.”

Read more here.

Want to view archived newsletters? Click Here!


Sign up to receive the latest neurofibromatosis news and information in your inbox!



Have a story you'd like to share with the NF community? Click Here!